Peptibase
Immune

Enfuvirtide

Also known as: Fuzeon, T-20

FDA Approved
Share:

Key Facts: Enfuvirtide

Category
Immune
FDA Status
FDA Approved
Clinical Status
FDA Approved - HIV salvage therapy
Administration
Subcutaneous injection twice daily
Typical Dose
Limited community data available
Frequency
See research protocols
Evidence Level
FDA Approved
Duration
Ongoing as part of HIV regimen
Also Known As
Fuzeon, T-20

What to Expect

A peptide HIV fusion inhibitor that blocks viral entry into cells. First approved drug in the fusion inhibitor class.

Mechanism of Action

Enfuvirtide is a 36-amino acid peptide that binds to HIV gp41, preventing the conformational change needed for virus-cell membrane fusion. This blocks HIV entry before the virus can infect the cell.

Research Summary

TORO trials showed significant viral load reduction in treatment-experienced patients. Reserved for salvage therapy due to twice-daily injection requirement and injection site reactions.

Clinical Status:FDA Approved - HIV salvage therapy
Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Research Dosingⓘ

Scientific studies

FDA-approved dosing

Doses from Studies

90 mg subcutaneous twice daily

FDA Approved Labeling - Prescribed dose ↗

Duration

Ongoing as part of HIV regimen

Administration

Subcutaneous injection twice daily

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Injection site reactions (98%)
  • ●Diarrhea
  • ●Nausea
  • ●Fatigue
  • ●Pneumonia (higher incidence)
  • ●Hypersensitivity reactions
  • ●FDA approved (Fuzeon)

References

Related Peptides

Peptides commonly compared with Enfuvirtide or used in similar applications.

LL-37

Clinical Trials

A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.

Immune

Thymosin Alpha-1

Clinical Trials

A naturally occurring thymic peptide that enhances immune function. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant.

Immune

KPV

Preclinical

A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.

Immune

VIP

Clinical Trials

A naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.

Immune

Semaglutide

FDA

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.

Weight Loss
How to Use EnfuvirtideEnfuvirtide AlternativesCompare with SimilarBrowse All Peptides

Want updates on Enfuvirtide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Educational Information Only

This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.

Back to all peptides